Ovarian Cancer Clinical Trials in Columbus, Ohio

18 studies are recruiting for ovarian cancer in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

    Stage
    Phase 2
    Ages
    18 to 99
    Site
    The Mark H Zangmeister Cancer Center Ohio, Columbus, Ohio
    Locations
    74 in total
    Run by
    Incyte Corporation

    See if you can join NCT07023627 on ClinicalTrials.gov

  2. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Ohio Health Research Institute, Columbus, Ohio
    Locations
    192 in total
    Run by
    Incyte Corporation

    See if you can join NCT07214779 on ClinicalTrials.gov

  3. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

    The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    29 in total
    Run by
    Tubulis GmbH

    See if you can join NCT06303505 on ClinicalTrials.gov

  4. Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

    This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Zangmeister Cancer Center, Columbus, Ohio
    Locations
    22 in total
    Run by
    Genmab

    See if you can join NCT07225270 on ClinicalTrials.gov

  5. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    16 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT04981119 on ClinicalTrials.gov

  6. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus, Ohio
    Locations
    196 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06824467 on ClinicalTrials.gov

  7. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

    The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

    Stage
    Phase 1
    Ages
    15 and older
    Site
    The Ohio State University, Columbus, Ohio
    Locations
    22 in total
    Run by
    Xencor, Inc.

    See if you can join NCT06276491 on ClinicalTrials.gov

  8. Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

    This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

    Stage
    Phase 1
    Ages
    18 to 130
    Site
    Research Site, Columbus, Ohio
    Locations
    60 in total
    Run by
    AstraZeneca

    See if you can join NCT05797168 on ClinicalTrials.gov

  9. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

    This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Ohio State University Wexner Medical Center, Columbus, Ohio
    Locations
    28 in total
    Run by
    Regeneron Pharmaceuticals

    See if you can join NCT04590326 on ClinicalTrials.gov

  10. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

    Stage
    Phase 2
    Ages
    18 to 130
    Site
    Research Site, Columbus, Ohio
    Locations
    96 in total
    Run by
    AstraZeneca

    See if you can join NCT05489211 on ClinicalTrials.gov

  11. A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

    This is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Site 0108, Columbus, Ohio
    Locations
    59 in total
    Run by
    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    See if you can join NCT07546500 on ClinicalTrials.gov

  12. Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    The proposed study design is a single arm Phase II trial to document the feasibility of carboplatin-mirvetuximab - in patients with advanced-stage EOC. Patients with biopsy confirmed, newly diagnosed, advanced-stage serous EOC deemed appropriate for NACT will have their tumors evaluated for FRα rec…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    9 in total
    Run by
    University of Alabama at Birmingham

    See if you can join NCT04606914 on ClinicalTrials.gov

  13. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

    Stage
    Phase 1
    Ages
    18 to 90
    Site
    Ohio State University, Columbus, Ohio
    Locations
    11 in total
    Run by
    Perspective Therapeutics

    See if you can join NCT06710756 on ClinicalTrials.gov

  14. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    12 in total
    Run by
    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

  15. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio
    Locations
    14 in total
    Run by
    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

  16. A Study of MT-4561 in Patients With Various Advanced Solid Tumors

    This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerab…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    6 in total
    Run by
    Tanabe Pharma America, Inc.

    See if you can join NCT06943521 on ClinicalTrials.gov

  17. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Columbus, Ohio
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  18. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    The Ohio State University Wexner Medical Center, Columbus, Ohio
    Locations
    7 in total
    Run by
    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.